Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction-Reference-Cited by-同舟云学术

Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction

Published:2015-03 Issue:5 Volume:11 Page:819-831
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Musunuru H Bindu¹²,Loblaw Andrew¹²³

Affiliation:

1. Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada

2. Department of Radiation Oncology, University of Toronto, Stewart Building, 149 College Street, Toronto, ON, M5T 1P5, Canada

3. Institute of Health Policy, Measurement & Evaluation, University of Toronto, Health Sciences Building, 155 College Street, Toronto, ON, M5T 3M6, Canada

Abstract

ABSTRACT Stereotactic body radiotherapy, also known as stereotactic ablative body radiotherapy (SABR), is an emerging treatment option for lung, prostate, liver and other tumors. Key factors in SABR are delivery of a high-dose radiation per fraction, proper patient positioning and target localization. Our review details the various radiotherapy techniques, dose fractionation schedules and toxicities for prostate SABR. Ongoing Phase II/III SABR studies across various risk groups have been included. It also discusses the role of conscientious focal dose escalation of the dominant intraprostatic nodule, integrating multiparametric MRI into radiotherapy protocols and finally cost–effectiveness of SABR.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon.15.14

Reference46 articles.

1. Fractionation and protraction for radiotherapy of prostate carcinoma

2. Cell production rates in human tissues and tumours and their significance. Part II: clinical data

3. Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9–2.2) Gy

4. Fractionation and late rectal toxicity

5. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of a Quality Metric Score to Assess the Placement of Hydrogel Rectal Spacer in Patients Treated With Prostate Stereotactic Radiation Therapy;Advances in Radiation Oncology;2024-03

2. Brachytherapy in Belgium in 2018. A national survey of the brachytherapy study group of the Belgian SocieTy for Radiotherapy and Oncology (BeSTRO);Radiotherapy and Oncology;2020-09

3. Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life;International Journal of Radiation Oncology*Biology*Physics;2018-12

4. Stereotactic ablative body radiotherapy in patients with prostate cancer;Translational Andrology and Urology;2018-06

5. UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016;Journal of Contemporary Brachytherapy;2018